{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:12:22Z","timestamp":1771467142579,"version":"3.50.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2018M3A9A70\u201357263"],"award-info":[{"award-number":["NRF-2018M3A9A70\u201357263"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.xphs.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T16:24:15Z","timestamp":1615047855000},"page":"2346-2354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2"],"prefix":"10.1016","volume":"110","author":[{"given":"K.Abraham","family":"Peele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shraddha","family":"Parate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krupanidhi","family":"Srirama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.C.","family":"Venkateswarulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.xphs.2021.03.004_bib0001","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat Microbiol"},{"issue":"3","key":"10.1016\/j.xphs.2021.03.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges","volume":"55","author":"Lai","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.xphs.2021.03.004_bib0003","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xphs.2021.03.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105948","article-title":"Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence","volume":"55","author":"Wang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.xphs.2021.03.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234765","article-title":"The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): a systematic review and meta-analysis of 148 studies from 9 countries","volume":"15","author":"Grant","year":"2020","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.xphs.2021.03.004_bib0006","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jiph.2020.03.019","article-title":"Coronavirus disease 2019 (COVID-19): a literature review","volume":"13","author":"Harapan","year":"2020","journal-title":"J Infect Public Health"},{"issue":"16","key":"10.1016\/j.xphs.2021.03.004_bib0007","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1128\/JVI.00080-16","article-title":"Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens","volume":"90","author":"Sexton","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.xphs.2021.03.004_bib0008","doi-asserted-by":"crossref","unstructured":"Valencia D.N. Brief review on COVID-19: the 2020 pandemic caused by SARS-CoV-2. Cureus 2020;12(3). doi:10.7759\/cureus.7386.","DOI":"10.7759\/cureus.7386"},{"key":"10.1016\/j.xphs.2021.03.004_bib0009","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3389\/fphar.2020.01196","article-title":"COVID-19 therapeutic options under investigation","volume":"11","author":"Kaddoura","year":"2020","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2021.03.004_bib0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1631\/jzus.B2000083","article-title":"An overview of COVID-19","volume":"21","author":"Shi","year":"2020","journal-title":"J Zhejiang Univ Sci B"},{"key":"10.1016\/j.xphs.2021.03.004_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111805","article-title":"Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic","volume":"146","author":"Vlachakis","year":"2020","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"10.1016\/j.xphs.2021.03.004_bib0012","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/ijp.IJP_338_20","article-title":"Update on the target structures of SARS-CoV-2: a systematic review","volume":"52","author":"Prajapat","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.xphs.2021.03.004_bib0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jare.2020.03.005","article-title":"COVID-19 infection: origin, transmission, and characteristics of human coronaviruses","volume":"24","author":"Shereen","year":"2020","journal-title":"J Adv Res"},{"issue":"2","key":"10.1016\/j.xphs.2021.03.004_bib0014","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2004.10.001","article-title":"Characterization of viral proteins encoded by the SARS-coronavirus genome","volume":"65","author":"Tan","year":"2005","journal-title":"Antiviral Res"},{"issue":"7","key":"10.1016\/j.xphs.2021.03.004_bib0015","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1128\/JVI.01472-06","article-title":"Role of the coronavirus E viroporin protein transmembrane domain in virus assembly","volume":"81","author":"Ye","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.xphs.2021.03.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4389089","article-title":"Sars-CoV-2 envelope and membrane proteins: structural differences linked to virus characteristics?","volume":"2020","author":"Bianchi","year":"2020","journal-title":"Biomed Res Int"},{"issue":"10","key":"10.1016\/j.xphs.2021.03.004_bib0017","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/jmv.20953","article-title":"The membrane protein of SARS-CoV suppresses NF-\u03baB activation","volume":"79","author":"Fang","year":"2007","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.xphs.2021.03.004_bib0018","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1042\/BJ20131461","article-title":"The SARS-coronavirus membrane protein induces apoptosis via interfering with PDK1PKB\/Akt signalling","volume":"464","author":"Tsoi","year":"2014","journal-title":"Biochem J"},{"key":"10.1016\/j.xphs.2021.03.004_bib0019","article-title":"Essential functional molecules associated with SARS-CoV-2 infection: potential therapeutic targets for COVID-19","author":"Rajarshi","year":"2020","journal-title":"Gene"},{"issue":"0","key":"10.1016\/j.xphs.2021.03.004_bib0020","first-page":"1","article-title":"A review on drug repurposing applicable to COVID-19","volume":"2020","author":"Dotolo","year":"2020","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.xphs.2021.03.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100719","article-title":"FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy","volume":"53","author":"Dro\u017cd\u017cal","year":"2020","journal-title":"Drug Resist Updat"},{"issue":"10","key":"10.1016\/j.xphs.2021.03.004_bib0022","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/2472555220942123","article-title":"RNA-dependent RNA polymerase as a target for COVID-19 drug discovery","volume":"25","author":"Zhu","year":"2020","journal-title":"SLAS Discov"},{"key":"10.1016\/j.xphs.2021.03.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112527","article-title":"A promising antiviral candidate drug for the COVID-19 pandemic: a mini-review of remdesivir","volume":"201","author":"Liang","year":"2020","journal-title":"Eur J Med Chem"},{"issue":"4","key":"10.1016\/j.xphs.2021.03.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","volume":"55","author":"Ko","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.xphs.2021.03.004_bib0025","doi-asserted-by":"crossref","unstructured":"Bhowmik D., Nandi R., Jagadeesan R., Kumar N., Prakash A., Kumar D. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. 2020. doi:10.1016\/j.meegid.2020.104451.","DOI":"10.1016\/j.meegid.2020.104451"},{"key":"10.1016\/j.xphs.2021.03.004_bib0026","article-title":"Repurposed drugs and nutraceuticals targeting envelope protein: a possible therapeutic strategy against COVID-19","author":"Das","year":"2020","journal-title":"Genomics"},{"key":"10.1016\/j.xphs.2021.03.004_bib0027","article-title":"A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem)","author":"Borkotoky","year":"2020","journal-title":"J Biomol Struct Dyn"},{"issue":"D1","key":"10.1016\/j.xphs.2021.03.004_bib0028","doi-asserted-by":"crossref","first-page":"D1137","DOI":"10.1093\/nar\/gkx1088","article-title":"SuperDRUG2: a one stop resource for approved\/marketed drugs","volume":"46","author":"Siramshetty","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.xphs.2021.03.004_bib0029","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/bioinformatics\/bti295","article-title":"Super drug: a conformational drug database","volume":"21","author":"Goede","year":"2005","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.xphs.2021.03.004_bib0030","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40495-020-00216-7","article-title":"An update on current therapeutic drugs treating COVID-19","volume":"6","author":"Wu","year":"2020","journal-title":"Curr Pharmacol Reports"},{"issue":"7792","key":"10.1016\/j.xphs.2021.03.004_bib0031","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-019-1923-7","article-title":"Improved protein structure prediction using potentials from deep learning","volume":"577","author":"Senior","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.xphs.2021.03.004_bib0032","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00109-020-01980-1","article-title":"Insights into the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 NSP6: in silico binding mechanistic analysis","volume":"98","author":"Pandey","year":"2020","journal-title":"J Mol Med"},{"issue":"2","key":"10.1016\/j.xphs.2021.03.004_bib0033","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J Appl Crystallogr"},{"issue":"9","key":"10.1016\/j.xphs.2021.03.004_bib0034","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/pro.5560020916","article-title":"Verification of protein structures: patterns of nonbonded atomic interactions","volume":"2","author":"Colovos","year":"1993","journal-title":"Protein Sci"},{"issue":"W1","key":"10.1016\/j.xphs.2021.03.004_bib0035","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gky473","article-title":"CASTp 3.0: computed atlas of surface topography of proteins","volume":"46","author":"Tian","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xphs.2021.03.004_bib0036","first-page":"1","article-title":"Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia","author":"Helal","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.xphs.2021.03.004_bib0037","first-page":"4","article-title":"A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing","volume":"19","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2021.03.004_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.128823","article-title":"Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein","volume":"1221","author":"Kulkarni","year":"2020","journal-title":"J Mol Struct"},{"key":"10.1016\/j.xphs.2021.03.004_bib0039","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","article-title":"Small-molecule library screening by docking with PyRx","volume":"1263","author":"Dallakyan","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"6","key":"10.1016\/j.xphs.2021.03.004_bib0040","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.xphs.2021.03.004_bib0041","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1741-7007-9-71","article-title":"Molecular dynamics simulations and drug discovery","volume":"9","author":"Durrant","year":"2011","journal-title":"BMC Biol"},{"issue":"11","key":"10.1016\/j.xphs.2021.03.004_bib0042","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/jcc.21816","article-title":"SwissParam: a fast force field generation tool for small organic molecules","volume":"32","author":"Zoete","year":"2011","journal-title":"J Comput Chem"},{"key":"10.1016\/j.xphs.2021.03.004_bib0043","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J Comput Chem"},{"key":"10.1016\/j.xphs.2021.03.004_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2020.104186","article-title":"A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment","volume":"130","author":"Kumar","year":"2021","journal-title":"Comput Biol Med"},{"issue":"1","key":"10.1016\/j.xphs.2021.03.004_bib0045","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations","volume":"51","author":"Hou","year":"2011","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.xphs.2021.03.004_bib0046","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jmgm.2018.12.006","article-title":"Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics","volume":"88","author":"Kumar","year":"2019","journal-title":"J Mol Graph Model"},{"issue":"7","key":"10.1016\/j.xphs.2021.03.004_bib0047","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"G-mmpbsa -A GROMACS tool for high-throughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J Chem Inf Model"},{"issue":"3","key":"10.1016\/j.xphs.2021.03.004_bib0048","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/10799893.2016.1212376","article-title":"Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation","volume":"37","author":"Bavi","year":"2017","journal-title":"J Recept Signal Transduct"},{"issue":"5","key":"10.1016\/j.xphs.2021.03.004_bib0049","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/jcm8050746","article-title":"Computational simulations identify pyrrolidine-2,3-dione derivatives as novel inhibitors of Cdk5\/p25 complex to attenuate Alzheimer's pathology","volume":"8","author":"Zeb","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.xphs.2021.03.004_bib0050","doi-asserted-by":"crossref","first-page":"342","DOI":"10.20411\/pai.v5i1.377","article-title":"The structure of the membrane protein of sars-cov-2 resembles the sugar transporter semisweet","volume":"5","author":"Thomas","year":"2020","journal-title":"Pathog Immun"},{"key":"10.1016\/j.xphs.2021.03.004_bib0051","first-page":"1","article-title":"Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes","author":"Elmezayen","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.xphs.2021.03.004_bib0052","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.compbiomed.2016.06.005","article-title":"Molecular interactions of UvrB protein and DNA from Helicobacter pylori: insight into a molecular modeling approach","volume":"75","author":"Bavi","year":"2016","journal-title":"Comput Biol Med"},{"issue":"1","key":"10.1016\/j.xphs.2021.03.004_bib0053","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-4682-10-22","article-title":"Homology modeling and virtual screening approaches to identify potent inhibitors of VEB-1 \u03b2-lactamase","volume":"10","author":"Messaoudi","year":"2013","journal-title":"Theor Biol Med Model"},{"key":"10.1016\/j.xphs.2021.03.004_bib0054","first-page":"1","article-title":"Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with Mpro","author":"Francis","year":"2020","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.xphs.2021.03.004_bib0055","first-page":"e04642","article-title":"Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz","author":"Jordaan","year":"2017","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.xphs.2021.03.004_bib0056","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.bpj.2009.11.011","article-title":"Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors","volume":"98","author":"Kuzmanic","year":"2010","journal-title":"Biophys J"},{"issue":"3","key":"10.1016\/j.xphs.2021.03.004_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119264","article-title":"Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis","volume":"10","author":"Mart\u00ednez","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.xphs.2021.03.004_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/364819","article-title":"Ligand-based and structure-based investigation for Alzheimer's disease from traditional Chinese medicine","volume":"2014","author":"Liao","year":"2014","journal-title":"Evidence-Based Complement Altern Med"},{"issue":"1","key":"10.1016\/j.xphs.2021.03.004_bib0059","first-page":"1","article-title":"Conformational dynamics, ligand binding and effects of mutations in NirE an S-Adenosyl-l-methionine dependent methyltransferase","volume":"6","author":"Singh","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.xphs.2021.03.004_bib0060","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/prot.21998","article-title":"fRMSDPred: predicting local RMSD between structural fragments using sequence information","volume":"72","author":"Rangwala","year":"2008","journal-title":"Proteins Struct Funct Genet"},{"key":"10.1016\/j.xphs.2021.03.004_bib0061","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.csbj.2019.04.010","article-title":"Computational simulations identified two candidate inhibitors of Cdk5\/p25 to abrogate tau-associated neurological disorders","volume":"17","author":"Zeb","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"issue":"22","key":"10.1016\/j.xphs.2021.03.004_bib0062","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.3390\/molecules24224116","article-title":"Identification of the fipronil resistance associated mutations in nilaparvata lugens GABA receptors by molecular modeling","volume":"24","author":"Tian","year":"2019","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.xphs.2021.03.004_bib0063","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1021\/acs.jcim.9b00609","article-title":"A comparative linear interaction energy and MM\/PBSA Study on SIRT1-ligand binding free energy calculation","volume":"59","author":"Rifai","year":"2019","journal-title":"J Chem Inf Model"},{"issue":"8","key":"10.1016\/j.xphs.2021.03.004_bib0064","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3390\/molecules25081971","article-title":"Application of MM-PBSA methods in virtual screening","volume":"25","author":"Poli","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.xphs.2021.03.004_bib0065","first-page":"1","article-title":"Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis","author":"Singh","year":"2020","journal-title":"J Biomol Struct Dyn"},{"issue":"4","key":"10.1016\/j.xphs.2021.03.004_bib0066","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10822-018-0105-2","article-title":"Protein\u2013ligand interfaces are polarized: discovery of a strong trend for intermolecular hydrogen bonds to favor donors on the protein side with implications for predicting and designing ligand complexes","volume":"32","author":"Raschka","year":"2018","journal-title":"J Comput Aided Mol Des"},{"issue":"4","key":"10.1016\/j.xphs.2021.03.004_bib0067","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40495-020-00225-6","article-title":"Colchicine in COVID-19: an old drug, new use","volume":"6","author":"Schlesinger","year":"2020","journal-title":"Curr Pharmacol Reports"},{"issue":"6","key":"10.1016\/j.xphs.2021.03.004_bib0068","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","article-title":"Colchicine today","volume":"73","author":"Niel","year":"2006","journal-title":"Jt Bone Spine"},{"issue":"4","key":"10.1016\/j.xphs.2021.03.004_bib0069","first-page":"328","article-title":"Rational design of colchicine derivatives as anti-HIV agents via QSAR and molecular docking","volume":"15","author":"Worachartcheewan","year":"2018","journal-title":"Med Chem (Los Angeles)"},{"issue":"4","key":"10.1016\/j.xphs.2021.03.004_bib0070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cmdc.201800641","article-title":"Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their hCE1-Activated prodrugs as antiviral agents","volume":"14","author":"Richter","year":"2019","journal-title":"Chem Med Chem"},{"issue":"45","key":"10.1016\/j.xphs.2021.03.004_bib0071","doi-asserted-by":"crossref","first-page":"26792","DOI":"10.1039\/D0RA04743K","article-title":"Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2","volume":"10","author":"Koulgi","year":"2020","journal-title":"RSC Adv"},{"issue":"32","key":"10.1016\/j.xphs.2021.03.004_bib0072","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1021\/acs.jpcb.0c04198","article-title":"Structural basis of the potential binding mechanism of remdesivir to SARS-CoV-2 RNA-dependent RNA polymerase","volume":"124","author":"Zhang","year":"2020","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.xphs.2021.03.004_bib0073","doi-asserted-by":"crossref","unstructured":"Gordon C.J., Tchesnokov E.P., Woolner E., et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. doi:10.1074\/jbc.RA120.013679.","DOI":"10.1074\/jbc.RA120.013679"},{"issue":"6498","key":"10.1016\/j.xphs.2021.03.004_bib0074","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science (80-)"},{"key":"10.1016\/j.xphs.2021.03.004_bib0075","unstructured":"FDA Approves First Treatment for COVID-19 | FDA.https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19. Accessed December 10, 2020."},{"key":"10.1016\/j.xphs.2021.03.004_bib0076","first-page":"1","article-title":"Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease\u2013in silico approach","author":"Naik","year":"2020","journal-title":"J Biomol Struct Dyn"},{"issue":"50","key":"10.1016\/j.xphs.2021.03.004_bib0077","doi-asserted-by":"crossref","first-page":"11337","DOI":"10.1021\/acs.jpcb.0c07312","article-title":"Remdesivir strongly binds to both RNA-dependent RNA polymerase and main protease of SARS-COV-2: Evidence from molecular simulations","volume":"124","author":"Nguyen","year":"2020","journal-title":"J Phys Chem B"},{"issue":"1","key":"10.1016\/j.xphs.2021.03.004_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-70863-9","article-title":"An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors","volume":"10","author":"Trezza","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2021.03.004_bib0079","series-title":"Computationally Repurposed Drugs and Natural Products Against RNA Dependent RNA Polymerase As Potential COVID-19 Therapies","author":"Piplani","year":"2020"},{"issue":"1","key":"10.1016\/j.xphs.2021.03.004_bib0080","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2011","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.xphs.2021.03.004_bib0081","unstructured":"Colchicine - StatPearls - NCBI Bookshelf. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431102\/. Accessed December 10, 2020."},{"key":"10.1016\/j.xphs.2021.03.004_bib0082","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921001519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921001519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:31:42Z","timestamp":1758360702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921001519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0022354921001519"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.03.004","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}